0101.KLSE TMC Life Sciences Bhd
- Market cap
- MYR 723M
- P/E
- 41.5x
- P/B
- 0.82x
- ROE
- 2.0%
- Dividend yield
- 0.45%
- Fundamental score
- 2.5/5
Ratios use the latest price and the fiscal year ending Aug 2026.
Is 0101.KLSE undervalued?
Graham number0101.KLSE trades 23.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TMC Life Sciences Bhd fundamental analysis
12 of 22 checks passedROE 0/2
Low return on equity (2.0%), below 10%.
ROA 0/1
Return on assets (1.6%) is below the industry median (3.7%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (382.0%) is above the 5-year average (-3.0% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (382.0%) is above the industry median (6.1%).
Revenue Growth 1/2
Revenue grew 8.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (16.7%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is 3.7x against interest expense, below 5x.
PE vs Market 0/1
PE (41.5x) is above the market median (11.4x).
PE vs Industry 0/1
PE (41.5x) is above the industry median (27.9x).
PBV 1/1
Price to book (0.8x) is below the industry median (2.2x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 34.2, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield (0.4%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 18.7%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
About TMC Life Sciences Bhd
TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. The company operates Thomson Hospital Kota Damansara hospital located in prime alcove of Kota Damansara. It is involved in providing multi-disciplinary tertiary care, traditional and complementary, obstetrics and gynaecology, fertility services; operating fertility centres and women clinics; property investment; providing pharmacy services and products; management support servi…
Full company profileTMC Life Sciences Bhd financial statements
TMC Life Sciences Bhd annual financial statements (MYR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 152M | 169M | 195M | 184M | 201M | 244M | 311M | 346M | 346M | 393M |
| Gross Profit | 99.5M | 112M | 138M | 46.1M | 134M | 168M | 221M | 112M | 228M | 99.2M |
| Operating Income | 27.2M | 33.1M | 38.2M | 16.7M | 27.9M | 33.9M | 49.4M | 55.2M | 7.64M | 27.6M |
| EBITDA | 38.5M | 46.1M | 49.4M | 34.4M | 41.1M | 50.1M | 76.3M | 90.8M | 50.5M | 64.9M |
| Net Income | 26.0M | 27.8M | 20.9M | 15.9M | 20.3M | 41.4M | 39.3M | 40.6M | 3.61M | 17.4M |
| EPS | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.00 | 0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 770M | 802M | 849M | 950M | 1.06B | 1.13B | 1.18B | 1.19B | 1.13B | 1.12B |
| Total Liabilities | 55.1M | 61.6M | 86.3M | 178M | 271M | 305M | 315M | 302M | 279M | 248M |
| Shareholders' Equity | 714M | 740M | 762M | 772M | 790M | 827M | 862M | 888M | 853M | 867M |
| Cash & Short-term Investments | 207M | 202M | 179M | 136M | 138M | 139M | 162M | 189M | 105M | 112M |
| Total Debt | 1.80M | 1.72M | 1.63M | 88.4M | 175M | 210M | 219M | 205M | 183M | 145M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 9.90M | 25.8M | 30.2M | 18.1M | 22.4M | 35.9M | 54.6M | 80.2M | 22.5M | 60.6M |
| Capital Expenditure | 14.7M | 35.3M | 61.5M | 137M | 104M | 68.7M | 34.5M | 28.5M | 41.1M | 13.7M |
| Free Cash Flow | -4.78M | -9.42M | -31.3M | -118M | -81.1M | -32.8M | 20.1M | 51.7M | -18.6M | 46.8M |
| Ratios | ||||||||||
| ROE | 3.6% | 3.8% | 2.7% | 2.1% | 2.6% | 5.0% | 4.6% | 4.6% | 0.4% | 2.0% |
| ROA | 3.4% | 3.5% | 2.5% | 1.7% | 1.9% | 3.7% | 3.3% | 3.4% | 0.3% | 1.6% |
| Net Profit Margin | 17.2% | 16.4% | 10.7% | 8.7% | 10.1% | 17.0% | 12.6% | 11.7% | 1.0% | 4.4% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.11x | 0.22x | 0.25x | 0.25x | 0.23x | 0.21x | 0.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
TMC Life Sciences Bhd dividends
- Dividend yield
- 0.45%
- Forward dividend
- 0.01 MYR
- Payout ratio
- 18.7%
- Ex-dividend date
- Dec 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | MYR 3.25M | 0.00 | 18.7% |
| 2025 | MYR 38.6M | 0.02 | 1,070.9% |
| 2024 | MYR 14.6M | 0.01 | 36.0% |
| 2023 | MYR 4.81M | 0.00 | 12.3% |
| 2022 | MYR 3.86M | 0.00 | 9.3% |
| 2021 | MYR 2.92M | 0.00 | 14.4% |
| 2020 | MYR 3.51M | 0.00 | 22.0% |
| 2019 | MYR 3.18M | 0.00 | 15.2% |
| 2018 | MYR 2.90M | 0.00 | 10.4% |
| 2017 | MYR 2.67M | 0.00 | 10.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 356:327 on Nov 21, 2011.
Who owns TMC Life Sciences Bhd
- Insiders 83.04%
- Institutions 0.01%
- Public & others 16.95%
- Shares outstanding 1.74B
- Free float 297M
TMC Life Sciences Bhd company profile
- Company name
- TMC Life Sciences Bhd
- Ticker
- 0101.KLSE
- ISIN
- MYQ0101OO004
- Exchange
- Kuala Lumpur Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- August
- Address
- No. 11, Jalan Teknologi, Petaling Jaya, Malaysia, 47810
- Phone
- 60 3 6287 1111
- Website
- tmclife.com
About TMC Life Sciences Bhd
TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. The company operates Thomson Hospital Kota Damansara hospital located in prime alcove of Kota Damansara. It is involved in providing multi-disciplinary tertiary care, traditional and complementary, obstetrics and gynaecology, fertility services; operating fertility centres and women clinics; property investment; providing pharmacy services and products; management support services; development, marketing, and management of healthcare programmes; and research and development activities, as well as fertility consultancy, laboratory, and embryology services. TMC Life Sciences Berhad was founded in 1994 and is based in Petaling Jaya, Malaysia. The company is a subsidiary of Sasteria (M) Pte. Ltd.
TMC Life Sciences Bhd management
7- Mr. Kheong Ng KanExecutive Vice Chairman · born 1955
- Dr. Ahmad Adzuan Bin Abdul RahmanGroup Chief Executive Officer · born 1977
- Mr. Yu Chee WongGroup Chief Financial Officer · born 1973
- Dr. Siva Kumaran P. JayaramanChief Operating Officer of Thomson Hospitals Sdn Bhd
- Ms. Mun Yee Chin MAICSAJoint Secretary
- Ms. Siew Chuan Chua FCIS, MAICSAJoint Secretary · born 1958
- Dr. Savitha DharanChief Executive Officer of Thomson Hospitals Sdn. Bhd. · born 1982